Nithya Balasubramanian, group chief financial officer at IKS Health, said the company’s operations are largely unaffected by H-1B visa issues because of its hiring model. “Our business model is not to send people from India to the United States. Whatever work we do in the United States, we hire people locally.”
IKS Health operates with a mix of onshore and offshore teams: its sales, customer success and implementation teams are based in the United States, while a large portion of its technology and manufacturing workforce is in India.
She highlighted the company’s partnership with Western Washington Medical Group (WWMG) as a key focus area. “The main goal is to set a benchmark for the degree of transformation we can achieve when the platform is implemented to its full potential. »
The collaboration, she explains, is structured through a management services organization (MSO), of which the doctors are also shareholders. “Doctors are shareholders in the MSO, so we benefit alongside them,” she said. IKS invested capital in MSO to help it expand its primary care network and increase its operational efficiency.
Read also |
Reasonable valuations, profits stabilizing: JPMorgan’s Sanjay Mookim expects near-term rebound and prefers consumer plays
According to Balasubramanian, IKS’s platform helps healthcare providers reduce administrative costs and improve efficiency. “Typically, clients spend about 15% of their income on administrative tasks, and we deliver the same to them, between 8% and 10%,” she said. “Over time, these physician groups also tend to realize an additional 5% increase in revenue from productivity gains.
Regarding growth expectations, she said the United States remains IKS Health’s most important market, contributing about 99% of its revenue. “We strongly believe there is a significant runway for growth in the U.S. We are blind — we are focused on execution there,” she said.
Read also | CGHS tariff revision a positive step for cancer care, says HCG’s BS Ajaikumar
The company aims to continue growing faster than the overall healthcare outsourcing market, which is growing around 12%. “We would like to grow several notches above that,” Balasubramanian said, adding that IKS expects its long-term margins to remain in the early to mid 30% range.
IKS Health, which has a market capitalization of ₹26,541.51 crore, has seen its shares fall by over 21% in the past year.
For the full interview, watch the attached video
Check out all the latest stock market updates here
(Edited by: alphadesk)
First publication: October 7, 2025 3:47 p.m. STI
